Shenyang Xingqi Pharmaceutical Co Ltd Tangible Net Worth Ratio
Shenyang Xingqi Pharmaceutical Co Ltd tangible net worth ratio. Shenyang Xingqi Pharmaceutical Co Ltd (300573) has a Tangible Net Worth Ratio of 88.3% as of September 2025. This metric is calculated by deducting intangible assets (CN¥218.01 Million) from net assets (CN¥1.86 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check asset allocation strategy of Shenyang Xingqi Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Shenyang Xingqi Pharmaceutical Co Ltd (2011–2024)
Tangible net worth ratio of Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024. This chart shows how Shenyang Xingqi Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 88.3%, reflecting net assets of CN¥1.86 Billion with intangible assets of CN¥218.01 Million CNY. See working capital to net assets of Shenyang Xingqi Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Shenyang Xingqi Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2011–2024)
Shenyang Xingqi Pharmaceutical Co Ltd tangible net worth ratio by year from 2011 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Shenyang Xingqi Pharmaceutical Co Ltd market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 87.8% | CN¥1.59 Billion | CN¥194.18 Million | CN¥2.13 Billion | ▼ -1.1 pp |
| 2023 | 88.9% | CN¥1.69 Billion | CN¥188.22 Million | CN¥2.02 Billion | ▼ -3.2 pp |
| 2022 | 92.1% | CN¥1.55 Billion | CN¥123.26 Million | CN¥1.78 Billion | ▼ -2.4 pp |
| 2021 | 94.5% | CN¥1.34 Billion | CN¥73.85 Million | CN¥1.69 Billion | ▲ +1.1 pp |
| 2020 | 93.5% | CN¥694.06 Million | CN¥45.43 Million | CN¥965.70 Million | ▼ -2.2 pp |
| 2019 | 95.6% | CN¥574.90 Million | CN¥25.08 Million | CN¥852.37 Million | ▼ -0.1 pp |
| 2018 | 95.8% | CN¥554.58 Million | CN¥23.49 Million | CN¥708.47 Million | ▲ +0.1 pp |
| 2017 | 95.6% | CN¥553.38 Million | CN¥24.07 Million | CN¥676.48 Million | ▲ +0.3 pp |
| 2016 | 95.4% | CN¥520.95 Million | CN¥24.03 Million | CN¥721.41 Million | ▲ +2.1 pp |
| 2015 | 93.3% | CN¥389.79 Million | CN¥26.09 Million | CN¥650.94 Million | ▲ +0.6 pp |
| 2014 | 92.7% | CN¥367.81 Million | CN¥26.81 Million | CN¥670.90 Million | ▲ +0.9 pp |
| 2013 | 91.8% | CN¥336.80 Million | CN¥27.60 Million | CN¥567.21 Million | ▲ +1.5 pp |
| 2012 | 90.3% | CN¥290.70 Million | CN¥28.07 Million | CN¥418.02 Million | ▲ +1.9 pp |
| 2011 | 88.4% | CN¥247.00 Million | CN¥28.60 Million | CN¥267.88 Million | — |